Takeda Pharmaceutical Company LIMITED

Takeda Pharmaceutical Company LIMITED is a global, Japan-based pharmaceutical company that specializes in developing and manufacturing innovative medical treatments and pharmaceutical products. As a registered vendor in the U.S. federal government's System for Award Management (SAM.gov), the company has been an active participant in federal contracting since 2011. Takeda operates as a parent organization and is classified as a for-profit organization, manufacturer of goods, and grants recipient, with a focus on providing advanced pharmaceutical solutions to government healthcare systems and agencies.

Through federal contract awards, Takeda Pharmaceutical Company LIMITED has consistently demonstrated expertise in supplying critical pharmaceutical products and medical research solutions to various federal agencies. The company's contract portfolio likely includes significant awards in therapeutic areas such as oncology, gastroenterology, neuroscience, and rare diseases. Federal agencies like the Department of Defense, Veterans Affairs, and National Institutes of Health have been potential key funding sources for Takeda's contract work. While specific details of individual contract awards are not provided, the company's registration suggests a comprehensive approach to federal contracting that spans multiple healthcare and pharmaceutical domains.

Regarding Indefinite Delivery/Indefinite Quantity (IDV) contracts, Takeda Pharmaceutical Company LIMITED has positioned itself to provide flexible, long-term pharmaceutical supply and research capabilities to federal agencies. These IDV contracts would enable the company to respond quickly to government healthcare needs, potentially covering areas like medical research, pharmaceutical supply chains, and specialized treatment development. The most recent federal contract award date of October 3, 2024, indicates the company maintains an active and current federal contracting status, suggesting ongoing relationships with government procurement entities and continued opportunities for pharmaceutical product and service delivery.